{
  "docId": "019de074-c46c-7261-862e-11078609bbd6",
  "docSlug": "94ed059236b735624310519badaf5152",
  "documentTitle": "Theravance Biopharma | Investor Conference Presentation Deck | 32 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 32,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "key_messages",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes a forest plot showing LS Mean (95% CI) for various OHQ questionnaire scores.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-c46c-7261-862e-11078609bbd6/11",
  "deckHref": "/decks/019de074-c46c-7261-862e-11078609bbd6",
  "deckJsonHref": "/decks/019de074-c46c-7261-862e-11078609bbd6.json",
  "deckAnchorHref": "/decks/019de074-c46c-7261-862e-11078609bbd6#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.55,
        "x": 0.05,
        "y": 0.35
      },
      "kind": "chart",
      "text": "Study 0170 OHQ Questionnaire Scores",
      "attrs": null,
      "subkind": "bar-horizontal",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58d2d29a-d2b6-4f0b-be01-6153f5f6ad97",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.65
      },
      "kind": "list",
      "text": "Available to patients with supine hypertension; Can be taken anytime of day/night; Potential to be combined with other drugs",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4044a44a-d735-4010-ad0b-2b8d900fd618",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.3
      },
      "kind": "list",
      "text": "Once-daily dosing, single 10mg tablet; Low dosing frequency improves compliance; Decreases caregiver burden",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ce031b26-6f78-48dd-bb02-8aa2b8b194b3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Reflects Theravance Biopharma's expectations... [disclaimer text]",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fa10daa-67ce-4582-8fd2-02d088949bee",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "The Unique Benefits of Ampreloxetine Treatment",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c8fe519d-f127-43c1-a849-660d961114a9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 10,
      "beatId": "ab237745-c709-455f-abbe-d8a9f18e1916",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Ampreloxetine as a unique solution for MSA symptoms, with a focus on its product positioning and benefits.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "7f6b888f-01a2-48da-9e93-f1fbf3089b2a",
      "evidence": "The presentation highlights the benefits of Ampreloxetine in addressing MSA symptoms.",
      "position": 0,
      "objective": "What are the consequences of not treating MSA symptoms effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}